Cargando…

A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors

B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Raf inhibitors (BRIs), 3D pharmacophore models were created using the Genetic Algorithm with Linear Assignment of Hypermolecular Alignment of Database (GALAHAD). The best pharmacophore model obtained wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Huiding, Chen, Lijun, Zhang, Jianqiang, Xie, Xiaoguang, Qiu, Kaixiong, Fu, Jijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490445/
https://www.ncbi.nlm.nih.gov/pubmed/26035757
http://dx.doi.org/10.3390/ijms160612307
_version_ 1782379505208262656
author Xie, Huiding
Chen, Lijun
Zhang, Jianqiang
Xie, Xiaoguang
Qiu, Kaixiong
Fu, Jijun
author_facet Xie, Huiding
Chen, Lijun
Zhang, Jianqiang
Xie, Xiaoguang
Qiu, Kaixiong
Fu, Jijun
author_sort Xie, Huiding
collection PubMed
description B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Raf inhibitors (BRIs), 3D pharmacophore models were created using the Genetic Algorithm with Linear Assignment of Hypermolecular Alignment of Database (GALAHAD). The best pharmacophore model obtained which was used in effective alignment of the data set contains two acceptor atoms, three donor atoms and three hydrophobes. In succession, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed on 39 imidazopyridine BRIs to build three dimensional quantitative structure-activity relationship (3D QSAR) models based on both pharmacophore and docking alignments. The CoMSIA model based on the pharmacophore alignment shows the best result (q(2) = 0.621, r(2)(pred) = 0.885). This 3D QSAR approach provides significant insights that are useful for designing potent BRIs. In addition, the obtained best pharmacophore model was used for virtual screening against the NCI2000 database. The hit compounds were further filtered with molecular docking, and their biological activities were predicted using the CoMSIA model, and three potential BRIs with new skeletons were obtained.
format Online
Article
Text
id pubmed-4490445
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44904452015-07-07 A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors Xie, Huiding Chen, Lijun Zhang, Jianqiang Xie, Xiaoguang Qiu, Kaixiong Fu, Jijun Int J Mol Sci Article B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Raf inhibitors (BRIs), 3D pharmacophore models were created using the Genetic Algorithm with Linear Assignment of Hypermolecular Alignment of Database (GALAHAD). The best pharmacophore model obtained which was used in effective alignment of the data set contains two acceptor atoms, three donor atoms and three hydrophobes. In succession, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed on 39 imidazopyridine BRIs to build three dimensional quantitative structure-activity relationship (3D QSAR) models based on both pharmacophore and docking alignments. The CoMSIA model based on the pharmacophore alignment shows the best result (q(2) = 0.621, r(2)(pred) = 0.885). This 3D QSAR approach provides significant insights that are useful for designing potent BRIs. In addition, the obtained best pharmacophore model was used for virtual screening against the NCI2000 database. The hit compounds were further filtered with molecular docking, and their biological activities were predicted using the CoMSIA model, and three potential BRIs with new skeletons were obtained. MDPI 2015-05-29 /pmc/articles/PMC4490445/ /pubmed/26035757 http://dx.doi.org/10.3390/ijms160612307 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xie, Huiding
Chen, Lijun
Zhang, Jianqiang
Xie, Xiaoguang
Qiu, Kaixiong
Fu, Jijun
A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors
title A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors
title_full A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors
title_fullStr A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors
title_full_unstemmed A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors
title_short A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors
title_sort combined pharmacophore modeling, 3d qsar and virtual screening studies on imidazopyridines as b-raf inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490445/
https://www.ncbi.nlm.nih.gov/pubmed/26035757
http://dx.doi.org/10.3390/ijms160612307
work_keys_str_mv AT xiehuiding acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT chenlijun acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT zhangjianqiang acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT xiexiaoguang acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT qiukaixiong acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT fujijun acombinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT xiehuiding combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT chenlijun combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT zhangjianqiang combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT xiexiaoguang combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT qiukaixiong combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors
AT fujijun combinedpharmacophoremodeling3dqsarandvirtualscreeningstudiesonimidazopyridinesasbrafinhibitors